These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 9027267)

  • 1. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.
    Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S
    Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
    Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K
    J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.
    Fish JE; Kemp JP; Lockey RF; Glass M; Hanby LA; Bonuccelli CM
    Clin Ther; 1997; 19(4):675-90. PubMed ID: 9377612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.
    Kelloway JS
    Ann Pharmacother; 1997 Sep; 31(9):1012-21. PubMed ID: 9296243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype.
    Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM
    Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids.
    Nelson HS; Nathan RA; Kalberg C; Yancey SW; Rickard KA
    MedGenMed; 2001 Jul; 3(4):3. PubMed ID: 11549982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses.
    Tashkin DP; Nathan RA; Howland WC; Minkwitz MC; Simonson SG; Bonuccelli CM
    J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):246-54. PubMed ID: 9949315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma outcome changes associated with use of the leukotriene-receptor antagonist zafirlukast.
    Klingman D; Bielory L; Wang Y; Silverman S; Bell CF; Joy KA; Dever MT; Jones DA
    Manag Care Interface; 2001 Feb; 14(2):62-6. PubMed ID: 11228819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.
    Adkins JC; Brogden RN
    Drugs; 1998 Jan; 55(1):121-44. PubMed ID: 9463793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids.
    Virchow JC; Prasse A; Naya I; Summerton L; Harris A
    Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial.
    Grossman J; Smith LJ; Wilson AM; Thyrum PT
    Ann Allergy Asthma Immunol; 1999 Apr; 82(4):361-9. PubMed ID: 10227334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy.
    Smith LJ; Hanby LA; Lavins BJ; Simonson SG
    Ann Allergy Asthma Immunol; 1998 Jul; 81(1):43-9. PubMed ID: 9690572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(2):285-315. PubMed ID: 11270943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.
    Lazarus SC; Wong HH; Watts MJ; Boushey HA; Lavins BJ; Minkwitz MC
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1725-30. PubMed ID: 9412547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-efficacy analysis of fluticasone propionate versus zafirlukast in patients with persistent asthma.
    Menendez R; Stanford RH; Edwards L; Kalberg C; Rickard K
    Pharmacoeconomics; 2001; 19(8):865-74. PubMed ID: 11596838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials.
    Barnes NC; Miller CJ
    Thorax; 2000 Jun; 55(6):478-83. PubMed ID: 10817796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of asthma with zafirlukast. Clinical experience and tolerability profile.
    Spector SL
    Drugs; 1996; 52 Suppl 6():36-46. PubMed ID: 8941502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma.
    Kemp JP; Minkwitz MC; Bonuccelli CM; Warren MS
    Chest; 1999 Feb; 115(2):336-42. PubMed ID: 10027429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children.
    Pearlman DS; Lampl KL; Dowling PJ; Miller CJ; Bonuccelli CM
    Clin Ther; 2000 Jun; 22(6):732-47. PubMed ID: 10929920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
    Knorr B; Franchi LM; Bisgaard H; Vermeulen JH; LeSouef P; Santanello N; Michele TM; Reiss TF; Nguyen HH; Bratton DL
    Pediatrics; 2001 Sep; 108(3):E48. PubMed ID: 11533366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.